PT-141: Uses, Benefits & Research

What is PT-141?

PT-141, known generically as bremelanotide and marketed as Vyleesi, is a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) and synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). With a molecular weight of 1,025.2 Da, it was FDA-approved in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — making it the first and only centrally acting melanocortin agonist approved for sexual dysfunction.

Unlike erectile dysfunction medications such as sildenafil (Viagra) that work by increasing blood flow to the genitals, bremelanotide works in the brain. It is administered as a 1.75 mg subcutaneous injection approximately 45 minutes before anticipated sexual activity, with a half-life of 1.7-2.5 hours and approximately 100% subcutaneous bioavailability. An earlier intranasal formulation was discontinued due to inferior bioavailability and side effect profile.

Bremelanotide is approved in the US (2019), Canada (2020), and Israel, with European and Australian regulatory reviews ongoing. It is not eligible for routine compounding as it is an FDA-approved product with active method-of-use patents through approximately 2030.

Mechanism of Action

Bremelanotide’s mechanism is fundamentally different from vascular-acting sexual dysfunction treatments. It activates melanocortin receptors in the hypothalamus — the brain’s control center for sexual desire:

Receptor Binding Profile

Receptor	Affinity (Ki)	Activity
MC4R (primary target)	0.2-0.7 nM	Full agonist
MC1R	0.6-1.2 nM	Agonist
MC3R	3-10 nM	Partial agonist
MC5R	10-50 nM	Weak agonist
MC2R (adrenal)	>100 nM	No activity

Signaling Cascade

1. MC4R activation in the hypothalamus triggers Gs protein coupling
2. Increased cAMP production activates the PKA/CREB transcription pathway
3. Enhanced dopamine release in the mesolimbic (reward) pathway
4. Modulation of oxytocin and serotonin circuits involved in sexual behavior
5. Net effect: increased sexual desire and reduced distress — centrally mediated

The lack of significant MC2R activity means bremelanotide does not stimulate adrenal cortisol production. Its primary sexual function effects are mediated through MC4R in hypothalamic circuits governing desire, not through peripheral vasodilation.

Clinical Evidence

Phase 3 Trials (RECONNECT Program)

The FDA approval was based on two pivotal Phase 3 trials enrolling 1,247 premenopausal women with HSDD:

Women (HSDD) — Key Efficacy Data:

• FSD (Female Sexual Function) desire domain: +0.35 vs placebo (p<0.001)
• Distress score: Significant reduction (p<0.001)
• Satisfying sexual events: +0.8/month (placebo-adjusted)

Off-Label Male Evidence

Endpoint	Result	Study
IIEF-EF score improvement	+5.2 points (p<0.001)	Phase 2 (PMID: 16276020)
Successful intercourse attempts	+30%	Phase 2 (PMID: 20378716)
PDE5 non-responder success rate	50-65%	Multiple studies

Total Evidence Base

• Total human studies: 60+
• Randomized controlled trials: ~20
• Phase 3 trials: 2 (RECONNECT program, n=1,247)
• Meta-analyses: 5+
• 52-week safety extension: Completed, safety maintained (PMID: 31893927)

Active Clinical Trials

Approximately 8 active trials as of March 2026, including extension studies (HFpEF), real-world male ED data collection, and studies in breast cancer survivors with sexual dysfunction.

Drug Interactions & Contraindications

Documented Interactions

Drug	Effect	Management
Nitrates	Severe hypotension risk	Contraindicated
Alpha-blockers	Hypotension	Avoid combination
Antihypertensives	Additive BP effects	Monitor blood pressure
PDE5 inhibitors	Potential synergy + hypotension risk	Monitor closely

Pharmacokinetic Notes

Bremelanotide is not a significant CYP450 substrate or inhibitor — it is metabolized primarily by tissue proteases, not hepatic enzymes. Alcohol shows no significant pharmacokinetic interaction but may increase nausea. Oral contraceptives do not interact.

Contraindications: Uncontrolled hypertension, cardiovascular disease (history of MI, stroke, CAD), known hypersensitivity to bremelanotide, and pregnancy (Category X). Breastfeeding is not recommended as excretion in milk is unknown.

Safety & Side Effects

Common Adverse Events (Phase 3 Data)

Adverse Event	Incidence	Severity
Nausea	20-40%	Mild-moderate, often transient
Headache	10-12%	Mild
Flushing/hot flashes	8-10%	Mild
Injection site reactions	3-5%	Mild
Dizziness	3-5%	Mild
Fatigue	2-4%	Mild
Transient hypertension	1-2%	Moderate — clinically significant

Serious Adverse Events

Cardiovascular events occurred in less than 0.1% of subjects. There is a theoretical melanoma risk from MC1R activation — annual skin examinations are recommended. Postural hypotension was reported in less than 0.5%.

No black box warning exists. No dependency or tolerance has been observed — long-term efficacy is maintained. Dosing is limited to a maximum of 1 dose per 24 hours and 8 doses per month.

Honest Bottom Line

Bremelanotide (Vyleesi) is an FDA-approved melanocortin receptor agonist with strong clinical evidence for treating hypoactive sexual desire disorder in premenopausal women, supported by two Phase 3 trials and 60+ human studies. It works through a unique central mechanism in the brain rather than increasing blood flow, making it effective for both women with HSDD and men with erectile dysfunction who do not respond to PDE5 inhibitors. Nausea affects 20-40% of users and is the most common side effect; the drug is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. Off-label use in men is widespread and supported by moderate evidence, though no formal FDA registration trial for male indications has been completed.